CAS: 261717-22-0

HMR 1098 is a κ-opioid receptor agonist that has shown to have the ability to protect against myocardial infarct in anesthetized animals and to increase ATP levels. This drug also has metabolic effects, as it can improve mitochondrial function and prevent mitochondrial membrane potential from being reduced by oxidative stress. HMR 1098 also prevents the activation of atp-sensitive K+ channels in ventricular myocardium, which leads to an increase in cardiac contractility and improved heart rate. This drug has been shown to be effective in vivo, as it was able to reduce infarct size in a rat model of myocardial infarct.

Clamikalant sodium (HMR 1098) is an ATP-dependent potassium channel (KATP) cardiac-selective blocker, used in the study of arrhythmias.